Loading…

Diabetes attenuates the minimum anaesthetic concentration (MAC) and MAC-blocking adrenergic response reducing actions of clonidine in rats

Background: It is well known that clonidine, an α2 agonist, reduces anaesthetic requirement and attenuates haemodynamic responses against noxious stimuli. However, the diabetic state is known to affect several functions of α2 adrenoceptors. We investigated the effects of streptozotocin (STZ)‐induced...

Full description

Saved in:
Bibliographic Details
Published in:Acta anaesthesiologica Scandinavica 2001-11, Vol.45 (10), p.1230-1234
Main Authors: Kita, T., Kagawa, K., Mammoto, T., Takada, K., Hayashi, Y., Mashimo, T., Kishi, Y.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4380-54d8bf0feb3f84c04ac9e8b1834c095acad397d7ea83ddc606cd0ccb7acac40e3
cites cdi_FETCH-LOGICAL-c4380-54d8bf0feb3f84c04ac9e8b1834c095acad397d7ea83ddc606cd0ccb7acac40e3
container_end_page 1234
container_issue 10
container_start_page 1230
container_title Acta anaesthesiologica Scandinavica
container_volume 45
creator Kita, T.
Kagawa, K.
Mammoto, T.
Takada, K.
Hayashi, Y.
Mashimo, T.
Kishi, Y.
description Background: It is well known that clonidine, an α2 agonist, reduces anaesthetic requirement and attenuates haemodynamic responses against noxious stimuli. However, the diabetic state is known to affect several functions of α2 adrenoceptors. We investigated the effects of streptozotocin (STZ)‐induced diabetes mellitus (DM) on these beneficial actions of clonidine in halothane‐anaesthetized rats. Methods: The rats were randomly assigned to one of three groups: diabetes (n=24, induced by 50 mg · kg−1 IV STZ), diabetes treated with insulin (n=24), or control (n=24). We evaluated the effects of clonidine on minimum anaesthetic concentration (MAC) and minimum concentration of halothane needed to suppress cardiovascular responses evoked by a noxious stimulus (MAC‐blocking adrenergic responses: MAC‐BAR) in each group. MAC and MAC‐BAR of halothane were determined by the tail clamp method. MAC‐BAR was defined as the MAC which attenuated haemodynamic responses within 10% following the tail clamp. Results: The diabetic state decreased MAC of halothane by approximately 10%, while MAC‐BAR of halothane had been little affected. In the diabetes group, MAC reducing action of clonidine (30 and 100 μg · kg−1, IV) was completely abolished and MAC‐BAR reducing action of clonidine was partially reduced (30 but not 100 μg · kg−1, IV). Insulin treatment preserved these actions of clonidine. Conclusion: It is suggested that the diabetic state attenuates the beneficial actions of clonidine and that insulin treatment of diabetes preserves these actions of clonidine.
doi_str_mv 10.1034/j.1399-6576.2001.451010.x
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72335785</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72335785</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4380-54d8bf0feb3f84c04ac9e8b1834c095acad397d7ea83ddc606cd0ccb7acac40e3</originalsourceid><addsrcrecordid>eNqNUdFu0zAUtRCIlcIvIPMAYg8pdm3HyduqAhuoHUIM8Wg59s1wlzjFTkT3C_vqOaTaXnnyuT7nHl-fi9AbShaUMP5ht6CsLLNcyHyxJIQuuKAkkYcnaPbAPEUzkrhMULk8QS9i3KWS8bJ8jk4olSzPpZihu49OV9BDxLrvwQ96hP1vwK3zrh1arL2GmC56Z7DpvAHfB927zuP329X6NPEWJ5BVTWdunL_G2gbwEK6TPkDcdz5CAnYw_0gztkbc1dg0nXfWecDO42QZX6JntW4ivDqec_Tz86er9UW2-Xb-Zb3aZIazgmSC26KqSQ0VqwtuCNemhKKiBUtFKbTRlpXSStAFs9bkJDeWGFPJxBhOgM3Ru8l3H7o_Q_qcal000DTaQzdEJZeMCVmIJCwnoQldjAFqtQ-u1eFWUaLGRaidGuNWY9xqXISaFqEOqff18ZGhasE-dh6TT4K3R4GORjd10N64-KjjRIoiTTJHZ5Pur2vg9v8nUKvVjwkni2yycLGHw4OFDjcql0wK9evyXG355ddys_2urtg9PcG3Iw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72335785</pqid></control><display><type>article</type><title>Diabetes attenuates the minimum anaesthetic concentration (MAC) and MAC-blocking adrenergic response reducing actions of clonidine in rats</title><source>Wiley</source><creator>Kita, T. ; Kagawa, K. ; Mammoto, T. ; Takada, K. ; Hayashi, Y. ; Mashimo, T. ; Kishi, Y.</creator><creatorcontrib>Kita, T. ; Kagawa, K. ; Mammoto, T. ; Takada, K. ; Hayashi, Y. ; Mashimo, T. ; Kishi, Y.</creatorcontrib><description>Background: It is well known that clonidine, an α2 agonist, reduces anaesthetic requirement and attenuates haemodynamic responses against noxious stimuli. However, the diabetic state is known to affect several functions of α2 adrenoceptors. We investigated the effects of streptozotocin (STZ)‐induced diabetes mellitus (DM) on these beneficial actions of clonidine in halothane‐anaesthetized rats. Methods: The rats were randomly assigned to one of three groups: diabetes (n=24, induced by 50 mg · kg−1 IV STZ), diabetes treated with insulin (n=24), or control (n=24). We evaluated the effects of clonidine on minimum anaesthetic concentration (MAC) and minimum concentration of halothane needed to suppress cardiovascular responses evoked by a noxious stimulus (MAC‐blocking adrenergic responses: MAC‐BAR) in each group. MAC and MAC‐BAR of halothane were determined by the tail clamp method. MAC‐BAR was defined as the MAC which attenuated haemodynamic responses within 10% following the tail clamp. Results: The diabetic state decreased MAC of halothane by approximately 10%, while MAC‐BAR of halothane had been little affected. In the diabetes group, MAC reducing action of clonidine (30 and 100 μg · kg−1, IV) was completely abolished and MAC‐BAR reducing action of clonidine was partially reduced (30 but not 100 μg · kg−1, IV). Insulin treatment preserved these actions of clonidine. Conclusion: It is suggested that the diabetic state attenuates the beneficial actions of clonidine and that insulin treatment of diabetes preserves these actions of clonidine.</description><identifier>ISSN: 0001-5172</identifier><identifier>EISSN: 1399-6576</identifier><identifier>DOI: 10.1034/j.1399-6576.2001.451010.x</identifier><identifier>PMID: 11736675</identifier><identifier>CODEN: AANEAB</identifier><language>eng</language><publisher>Copenhagen: Munksgaard International Publishers</publisher><subject>Adrenergic alpha-Agonists - pharmacology ; Anesthesia, Inhalation ; Anesthetics, Inhalation - pharmacokinetics ; Anesthetics. Neuromuscular blocking agents ; Animals ; Biological and medical sciences ; clonidine ; Clonidine - pharmacology ; Diabetes mellitus ; Diabetes Mellitus, Experimental - drug therapy ; Diabetes Mellitus, Experimental - physiopathology ; Halothane - pharmacokinetics ; Hemodynamics - drug effects ; Insulin - therapeutic use ; MAC-BAR ; Male ; Medical sciences ; minimum anesthetic concentration (MAC) ; Neuropharmacology ; Pain Threshold - drug effects ; Pharmacology. Drug treatments ; Rats ; Rats, Sprague-Dawley ; α2 adrenoceptor</subject><ispartof>Acta anaesthesiologica Scandinavica, 2001-11, Vol.45 (10), p.1230-1234</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4380-54d8bf0feb3f84c04ac9e8b1834c095acad397d7ea83ddc606cd0ccb7acac40e3</citedby><cites>FETCH-LOGICAL-c4380-54d8bf0feb3f84c04ac9e8b1834c095acad397d7ea83ddc606cd0ccb7acac40e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14075823$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11736675$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kita, T.</creatorcontrib><creatorcontrib>Kagawa, K.</creatorcontrib><creatorcontrib>Mammoto, T.</creatorcontrib><creatorcontrib>Takada, K.</creatorcontrib><creatorcontrib>Hayashi, Y.</creatorcontrib><creatorcontrib>Mashimo, T.</creatorcontrib><creatorcontrib>Kishi, Y.</creatorcontrib><title>Diabetes attenuates the minimum anaesthetic concentration (MAC) and MAC-blocking adrenergic response reducing actions of clonidine in rats</title><title>Acta anaesthesiologica Scandinavica</title><addtitle>Acta Anaesthesiol Scand</addtitle><description>Background: It is well known that clonidine, an α2 agonist, reduces anaesthetic requirement and attenuates haemodynamic responses against noxious stimuli. However, the diabetic state is known to affect several functions of α2 adrenoceptors. We investigated the effects of streptozotocin (STZ)‐induced diabetes mellitus (DM) on these beneficial actions of clonidine in halothane‐anaesthetized rats. Methods: The rats were randomly assigned to one of three groups: diabetes (n=24, induced by 50 mg · kg−1 IV STZ), diabetes treated with insulin (n=24), or control (n=24). We evaluated the effects of clonidine on minimum anaesthetic concentration (MAC) and minimum concentration of halothane needed to suppress cardiovascular responses evoked by a noxious stimulus (MAC‐blocking adrenergic responses: MAC‐BAR) in each group. MAC and MAC‐BAR of halothane were determined by the tail clamp method. MAC‐BAR was defined as the MAC which attenuated haemodynamic responses within 10% following the tail clamp. Results: The diabetic state decreased MAC of halothane by approximately 10%, while MAC‐BAR of halothane had been little affected. In the diabetes group, MAC reducing action of clonidine (30 and 100 μg · kg−1, IV) was completely abolished and MAC‐BAR reducing action of clonidine was partially reduced (30 but not 100 μg · kg−1, IV). Insulin treatment preserved these actions of clonidine. Conclusion: It is suggested that the diabetic state attenuates the beneficial actions of clonidine and that insulin treatment of diabetes preserves these actions of clonidine.</description><subject>Adrenergic alpha-Agonists - pharmacology</subject><subject>Anesthesia, Inhalation</subject><subject>Anesthetics, Inhalation - pharmacokinetics</subject><subject>Anesthetics. Neuromuscular blocking agents</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>clonidine</subject><subject>Clonidine - pharmacology</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus, Experimental - drug therapy</subject><subject>Diabetes Mellitus, Experimental - physiopathology</subject><subject>Halothane - pharmacokinetics</subject><subject>Hemodynamics - drug effects</subject><subject>Insulin - therapeutic use</subject><subject>MAC-BAR</subject><subject>Male</subject><subject>Medical sciences</subject><subject>minimum anesthetic concentration (MAC)</subject><subject>Neuropharmacology</subject><subject>Pain Threshold - drug effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>α2 adrenoceptor</subject><issn>0001-5172</issn><issn>1399-6576</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNqNUdFu0zAUtRCIlcIvIPMAYg8pdm3HyduqAhuoHUIM8Wg59s1wlzjFTkT3C_vqOaTaXnnyuT7nHl-fi9AbShaUMP5ht6CsLLNcyHyxJIQuuKAkkYcnaPbAPEUzkrhMULk8QS9i3KWS8bJ8jk4olSzPpZihu49OV9BDxLrvwQ96hP1vwK3zrh1arL2GmC56Z7DpvAHfB927zuP329X6NPEWJ5BVTWdunL_G2gbwEK6TPkDcdz5CAnYw_0gztkbc1dg0nXfWecDO42QZX6JntW4ivDqec_Tz86er9UW2-Xb-Zb3aZIazgmSC26KqSQ0VqwtuCNemhKKiBUtFKbTRlpXSStAFs9bkJDeWGFPJxBhOgM3Ru8l3H7o_Q_qcal000DTaQzdEJZeMCVmIJCwnoQldjAFqtQ-u1eFWUaLGRaidGuNWY9xqXISaFqEOqff18ZGhasE-dh6TT4K3R4GORjd10N64-KjjRIoiTTJHZ5Pur2vg9v8nUKvVjwkni2yycLGHw4OFDjcql0wK9evyXG355ddys_2urtg9PcG3Iw</recordid><startdate>200111</startdate><enddate>200111</enddate><creator>Kita, T.</creator><creator>Kagawa, K.</creator><creator>Mammoto, T.</creator><creator>Takada, K.</creator><creator>Hayashi, Y.</creator><creator>Mashimo, T.</creator><creator>Kishi, Y.</creator><general>Munksgaard International Publishers</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200111</creationdate><title>Diabetes attenuates the minimum anaesthetic concentration (MAC) and MAC-blocking adrenergic response reducing actions of clonidine in rats</title><author>Kita, T. ; Kagawa, K. ; Mammoto, T. ; Takada, K. ; Hayashi, Y. ; Mashimo, T. ; Kishi, Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4380-54d8bf0feb3f84c04ac9e8b1834c095acad397d7ea83ddc606cd0ccb7acac40e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adrenergic alpha-Agonists - pharmacology</topic><topic>Anesthesia, Inhalation</topic><topic>Anesthetics, Inhalation - pharmacokinetics</topic><topic>Anesthetics. Neuromuscular blocking agents</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>clonidine</topic><topic>Clonidine - pharmacology</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus, Experimental - drug therapy</topic><topic>Diabetes Mellitus, Experimental - physiopathology</topic><topic>Halothane - pharmacokinetics</topic><topic>Hemodynamics - drug effects</topic><topic>Insulin - therapeutic use</topic><topic>MAC-BAR</topic><topic>Male</topic><topic>Medical sciences</topic><topic>minimum anesthetic concentration (MAC)</topic><topic>Neuropharmacology</topic><topic>Pain Threshold - drug effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>α2 adrenoceptor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kita, T.</creatorcontrib><creatorcontrib>Kagawa, K.</creatorcontrib><creatorcontrib>Mammoto, T.</creatorcontrib><creatorcontrib>Takada, K.</creatorcontrib><creatorcontrib>Hayashi, Y.</creatorcontrib><creatorcontrib>Mashimo, T.</creatorcontrib><creatorcontrib>Kishi, Y.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta anaesthesiologica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kita, T.</au><au>Kagawa, K.</au><au>Mammoto, T.</au><au>Takada, K.</au><au>Hayashi, Y.</au><au>Mashimo, T.</au><au>Kishi, Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diabetes attenuates the minimum anaesthetic concentration (MAC) and MAC-blocking adrenergic response reducing actions of clonidine in rats</atitle><jtitle>Acta anaesthesiologica Scandinavica</jtitle><addtitle>Acta Anaesthesiol Scand</addtitle><date>2001-11</date><risdate>2001</risdate><volume>45</volume><issue>10</issue><spage>1230</spage><epage>1234</epage><pages>1230-1234</pages><issn>0001-5172</issn><eissn>1399-6576</eissn><coden>AANEAB</coden><abstract>Background: It is well known that clonidine, an α2 agonist, reduces anaesthetic requirement and attenuates haemodynamic responses against noxious stimuli. However, the diabetic state is known to affect several functions of α2 adrenoceptors. We investigated the effects of streptozotocin (STZ)‐induced diabetes mellitus (DM) on these beneficial actions of clonidine in halothane‐anaesthetized rats. Methods: The rats were randomly assigned to one of three groups: diabetes (n=24, induced by 50 mg · kg−1 IV STZ), diabetes treated with insulin (n=24), or control (n=24). We evaluated the effects of clonidine on minimum anaesthetic concentration (MAC) and minimum concentration of halothane needed to suppress cardiovascular responses evoked by a noxious stimulus (MAC‐blocking adrenergic responses: MAC‐BAR) in each group. MAC and MAC‐BAR of halothane were determined by the tail clamp method. MAC‐BAR was defined as the MAC which attenuated haemodynamic responses within 10% following the tail clamp. Results: The diabetic state decreased MAC of halothane by approximately 10%, while MAC‐BAR of halothane had been little affected. In the diabetes group, MAC reducing action of clonidine (30 and 100 μg · kg−1, IV) was completely abolished and MAC‐BAR reducing action of clonidine was partially reduced (30 but not 100 μg · kg−1, IV). Insulin treatment preserved these actions of clonidine. Conclusion: It is suggested that the diabetic state attenuates the beneficial actions of clonidine and that insulin treatment of diabetes preserves these actions of clonidine.</abstract><cop>Copenhagen</cop><pub>Munksgaard International Publishers</pub><pmid>11736675</pmid><doi>10.1034/j.1399-6576.2001.451010.x</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0001-5172
ispartof Acta anaesthesiologica Scandinavica, 2001-11, Vol.45 (10), p.1230-1234
issn 0001-5172
1399-6576
language eng
recordid cdi_proquest_miscellaneous_72335785
source Wiley
subjects Adrenergic alpha-Agonists - pharmacology
Anesthesia, Inhalation
Anesthetics, Inhalation - pharmacokinetics
Anesthetics. Neuromuscular blocking agents
Animals
Biological and medical sciences
clonidine
Clonidine - pharmacology
Diabetes mellitus
Diabetes Mellitus, Experimental - drug therapy
Diabetes Mellitus, Experimental - physiopathology
Halothane - pharmacokinetics
Hemodynamics - drug effects
Insulin - therapeutic use
MAC-BAR
Male
Medical sciences
minimum anesthetic concentration (MAC)
Neuropharmacology
Pain Threshold - drug effects
Pharmacology. Drug treatments
Rats
Rats, Sprague-Dawley
α2 adrenoceptor
title Diabetes attenuates the minimum anaesthetic concentration (MAC) and MAC-blocking adrenergic response reducing actions of clonidine in rats
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T12%3A09%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diabetes%20attenuates%20the%20minimum%20anaesthetic%20concentration%20(MAC)%20and%20MAC-blocking%20adrenergic%20response%20reducing%20actions%20of%20clonidine%20in%20rats&rft.jtitle=Acta%20anaesthesiologica%20Scandinavica&rft.au=Kita,%20T.&rft.date=2001-11&rft.volume=45&rft.issue=10&rft.spage=1230&rft.epage=1234&rft.pages=1230-1234&rft.issn=0001-5172&rft.eissn=1399-6576&rft.coden=AANEAB&rft_id=info:doi/10.1034/j.1399-6576.2001.451010.x&rft_dat=%3Cproquest_cross%3E72335785%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4380-54d8bf0feb3f84c04ac9e8b1834c095acad397d7ea83ddc606cd0ccb7acac40e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=72335785&rft_id=info:pmid/11736675&rfr_iscdi=true